PeptidePlaza
The Free Peptide Reference

Plecanatide

From PeptidePlaza, the free peptide reference · Entry #1091 · Metabolic · Sources fetched 2026-09-11 · Editorial standards

Research warning. WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS. TRULANCE is contraindicated in patients less than 6 years of age; in nonclinical studies in young juvenile mice, administration of a single oral dose of plecanatide caused deaths due to dehydration. Avoid use of TRULANCE in patients 6 years to less than 18 years of age.

Plecanatide (also known as Trulance, Guanilib, plecanatida, SP-304 (SYNERGY)) is a metabolic research peptide. Plecanatide, also known as Trulance, is a guanylate cyclase-C agonist approved for treating chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) in adults.

Plecanatide is a heat-stable enterotoxin receptor agonist that works by stimulating guanylate cyclase-C (GC-C). This action increases intestinal fluid secretion, which helps to alleviate constipation. It is FDA-approved for oral administration in adults for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). Research on plecanatide includes its effectiveness for constipation and bloating in IBS patients, and comparisons with other treatments for constipation-predominant irritable bowel syndrome.

1 Mechanism of action

Heat-stable enterotoxin receptor agonist (agonist)

Primary targets: Heat-stable enterotoxin receptor

2 Reported effects

Effects below are those reported in the published literature cited on this page. They are not claims of clinical benefit and not medical advice.

2.1 Indicated / studied for

  • Chronic idiopathic constipation (CIC)
  • Irritable bowel syndrome with constipation (IBS-C)

2.2 Side effects

  • Diarrhea

3 Chemical and physical properties

CAS number467426-54-6
Molar mass1681.9 g/mol
Purity (typical)Not independently verified
Brand namesTrulance Immediate release
RouteORAL
Storage−20 °C, lyophilised powder, desiccated
SolubilitySterile water / bacteriostatic water
Receptors / targetsHeat-stable enterotoxin receptor

3.1 Amino acid sequence

Asn-Asp-Glu-Cys-Glu-Leu-Cys-Val-Asn-Val-Ala-Cys-Thr-Gly-Cys-Leu (disulfides 4–12, 7–15)

4 Research dosages

3 mg taken orally once daily

Dosages are reported from published protocols for reference only. Research chemicals are not for human consumption.

5 Research studies (8)

  1. American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation
    Gastroenterology (2023)
  2. Constipation-predominant irritable bowel syndrome treatment options Linaclotide, Lubiprostone, Plecanatide, and Tenapanor: analysis of the FDA Adverse Event Reporting System (FAERS) database
    Expert opinion on drug safety (2025)
  3. The Effectiveness of Plecanatide for Treating Constipation and Bloating in Patients Aged 18 to 40 Years With Irritable Bowel Syndrome: Utilization of a New Composite Trisymptom Endpoint
    Journal of gastroenterology and hepatology (2025) · RCT
  4. American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation
    The American journal of gastroenterology (2023)
  5. Plecanatide
    (2006) · Review
  6. AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Constipation
    Gastroenterology (2022)
  7. Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis
    The lancet. Gastroenterology & hepatology (2019) · Systematic Review
  8. Efficacy and Safety of Plecanatide in Chinese Patients with Functional Constipation: A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
    Drugs (2025) · RCT

6 Safety and risk profile

6.1 Regulatory status

Plecanatide is currently classified as FDA approved. Approval applies to specific clinical indications and dosing; research-grade material is not the approved product.

6.2 Contraindications

Conditions and populations in which use is contraindicated:

  • Patients less than 6 years of age
  • Patients with known or suspected mechanical gastrointestinal obstruction

6.3 Long-term risks

  • severe diarrhea
  • serious dehydration in pediatric patients

6.4 Research best practices

  • Store at room temperature, 20 to 25C (68 to 77F)
  • Keep in a dry place
  • Protect from moisture
  • Keep in the original bottle. Do not remove desiccant. Do not subdivide or repackage.
Safety data disclaimer. Safety assessments are based on published literature and are for educational reference only. Clinical evidence varies significantly between peptides. Always consult primary research and current regulatory guidance.

7 Frequently asked questions

What is Plecanatide used for?
Plecanatide, marketed as Trulance, is indicated for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) in adults. It helps to relieve symptoms associated with these conditions.
How does Plecanatide work?
Plecanatide acts as a guanylate cyclase-C (GC-C) agonist. By stimulating GC-C, it increases fluid secretion into the intestines, which aids in softening stools and promoting bowel movements, thereby alleviating constipation.
Is Plecanatide FDA approved?
Yes, Plecanatide was first approved by the FDA in 2017. It is available as an immediate-release oral medication for adults with chronic idiopathic constipation or irritable bowel syndrome with constipation.
What are the side effects of Plecanatide?
The most common adverse reaction reported with Plecanatide is diarrhea. Patients may experience severe diarrhea, and if this occurs, dosing should be suspended and the patient rehydrated.
What are the contraindications for Plecanatide?
Plecanatide is contraindicated in patients less than 6 years of age due to the risk of serious dehydration. It is also contraindicated in patients with a known or suspected mechanical gastrointestinal obstruction.

8 References

  1. Plecanatide — compound summary PubChem. View source
  2. Plecanatide — molecule record ChEMBL. View source
  3. Plecanatide — FDA approved prescribing information U.S. Food and Drug Administration. View source
  4. Plecanatide — published literature (125 records) PubMed. View source

Related compounds

Entries that share a target, a mechanism, or a research area with Plecanatide.

Gastrinmetabolic

Also metabolic

Gastrin is an endogenous human peptide that stimulates the stomach mucosa to produce and secrete hydrochloric acid and the pancreas to secrete digestive enzymes.

Ghrelinmetabolic

Also metabolic

Ghrelin is a peptide hormone that acts as a ligand for the growth hormone secretagogue receptor (GHSR). It is involved in regulating appetite, metabolism, and growth hormone release.

Seractide Acetateapproved

Also metabolic

Seractide Acetate is a synthetic peptide that acts as a melanocortin receptor 2 agonist.

Parathyroid Hormoneapproved

Also metabolic

Parathyroid Hormone is an 84-residue peptide that acts as a parathyroid hormone receptor agonist. It is FDA approved and marketed as Bestmade Natural Products BM67.

Octreotideapproved

Also metabolic

Octreotide is a somatostatin analog indicated for reducing growth hormone and IGF-1 levels in acromegaly, and for managing severe diarrhea and flushing associated with metastatic carcinoid tumors and VIPomas.

Liraglutideapproved

Also metabolic

The GLP-1 that proved the class. A C16 palmitoyl chain gave native GLP-1 a 13-hour half-life instead of two minutes — and produced the first cardiovascular outcome data for the family.

9 See also

For research reference only. Not medical advice. Peptides may be regulated or restricted in your jurisdiction. Entry validated by the PeptidePlaza Biomedical Research Desk; see editorial standards.